Potassium voltage-gated channel subfamily F member 1 (Kv5.1)

Potassium voltage-gated channel subfamily F member 1 (Kv5.1) is a regulatory alpha-subunit belonging to the family of voltage-gated potassium channels. Unlike typical pore-forming subunits that generate potassium currents on their own, Kv5.1 is considered an "electrically silent" or modulatory subunit—it does not form functional homotetrameric channels by itself but instead heterotetramerizes with other members such as KCNB1 (Kv2.1) or KCNB2 to modulate their expression and gating kinetics[3][7]. This modulation affects the deactivation upon repolarization and inactivation during maintained depolarization phases of the action potential. Kv5.1 is encoded by the intronless gene KCNF1 and is expressed broadly across tissues including heart, skeletal muscle, brain, kidney, and pancreas[6]. Its biological roles are primarily related to fine-tuning electrical signaling in excitable cells through its effects on other voltage-gated potassium channels rather than direct ion conduction. Diseases associated with alterations or dysregulation of this gene include prostate cancer and possibly non-small cell lung cancer[4][6]. There are currently no well-established drugs known to directly target this specific modulatory subunit nor established biomarkers or safety concerns unique to it. In summary, while not a classical drug target due to its lack of independent activity as an ion-conducting channel protein, Potassium voltage-gated channel subfamily F member 1 plays a significant role as a regulatory component within larger heteromeric potassium channel complexes that influence cellular excitability across multiple tissue types[3][7].

Other names

Kv5.1KCNF1kcnf1KH1IK8KCNFMGC33316